BRPI0412512A - método de tratamento ou prevenção de distúrbios do sistema nervoso central com compostos tendo seletividade para a subunidade alfa 3 do receptor de benzodiazepina - Google Patents

método de tratamento ou prevenção de distúrbios do sistema nervoso central com compostos tendo seletividade para a subunidade alfa 3 do receptor de benzodiazepina

Info

Publication number
BRPI0412512A
BRPI0412512A BRPI0412512-6A BRPI0412512A BRPI0412512A BR PI0412512 A BRPI0412512 A BR PI0412512A BR PI0412512 A BRPI0412512 A BR PI0412512A BR PI0412512 A BRPI0412512 A BR PI0412512A
Authority
BR
Brazil
Prior art keywords
nervous system
central nervous
selectivity
compounds
system disorders
Prior art date
Application number
BRPI0412512-6A
Other languages
English (en)
Inventor
Barbara Langen
Chris Rundfeldt
Rita Dost
Harmut Lueddens
Holger Rabe
Original Assignee
Elbion Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elbion Ag filed Critical Elbion Ag
Publication of BRPI0412512A publication Critical patent/BRPI0412512A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"MéTODO DE TRATAMENTO OU PREVENçãO DE DISTúRBIOS DO SISTEMA NERVOSO CENTRAL COM COMPOSTOS TENDO SELETIVIDADE PARA A SUBUNIDADE ALFA 3 DO RECEPTOR DE BENZODIAZEPINA". A presente invenção refere-se ao uso de 1-ar (alq) ilimidazolin-2onas que contêm um radical amina dissubstituído na posição 4 para o tratamento ou prevenção de distúrbios do sistema nervoso central incluindo depressão, ansiedade, distúrbios do movimento, e especialmente distonia, e distúrbios psicóticos, e especialmente esquizofrenia e sintomas psicóticos associados com outros distúrbios mentais.
BRPI0412512-6A 2003-07-11 2004-06-28 método de tratamento ou prevenção de distúrbios do sistema nervoso central com compostos tendo seletividade para a subunidade alfa 3 do receptor de benzodiazepina BRPI0412512A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48667803P 2003-07-11 2003-07-11
PCT/EP2004/006989 WO2005004867A2 (en) 2003-07-11 2004-06-28 Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor

Publications (1)

Publication Number Publication Date
BRPI0412512A true BRPI0412512A (pt) 2006-09-19

Family

ID=34062138

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412512-6A BRPI0412512A (pt) 2003-07-11 2004-06-28 método de tratamento ou prevenção de distúrbios do sistema nervoso central com compostos tendo seletividade para a subunidade alfa 3 do receptor de benzodiazepina

Country Status (17)

Country Link
US (2) US20050032863A1 (pt)
EP (2) EP2027856A1 (pt)
JP (1) JP2009513539A (pt)
KR (1) KR20060032633A (pt)
CN (2) CN1822836A (pt)
AR (1) AR045013A1 (pt)
AU (1) AU2004255414A1 (pt)
BR (1) BRPI0412512A (pt)
CA (1) CA2531861A1 (pt)
MX (1) MXPA05013196A (pt)
NO (1) NO20060686L (pt)
NZ (1) NZ544251A (pt)
RU (1) RU2354377C2 (pt)
TW (1) TW200512197A (pt)
UA (1) UA87982C2 (pt)
WO (1) WO2005004867A2 (pt)
ZA (1) ZA200509169B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2642859A1 (en) * 2006-03-08 2007-09-13 F. Hoffmann-La Roche Ag 4-amino-1,5-substituted 1,5-dihydro-imidazol-2-ones
CA2773038A1 (en) 2009-09-04 2011-03-10 P. Jeffrey Conn Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
RU2014109079A (ru) 2011-08-12 2015-09-20 Бёрингер Ингельхайм Ветмедика Гмбх Фармацевтическая композиция с маскированным вкусом
CN104199105A (zh) * 2014-08-27 2014-12-10 中国石油天然气集团公司 高密度三维勘探中初至的拾取方法及拾取装置
CN109564229A (zh) * 2016-07-11 2019-04-02 兰维尔健康有限公司 基于味觉识别的诊断相关性的方法
KR102489109B1 (ko) * 2020-06-02 2023-01-16 부산대학교 산학협력단 아세틸콜린 수용체 변이 유전자를 유효성분으로 포함하는 근긴장 이상증 치료용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI90869C (fi) * 1986-11-14 1994-04-11 Tanabe Seiyaku Co Menetelmä lääkeaineena käyttökelpoisten imidatsolidinonijohdannaisten valmistamiseksi
AU5884696A (en) 1995-06-23 1997-01-22 Bausch & Lomb Incorporated Method for cleaning contact lenses utilizing polysulfonates
US5869481A (en) * 1995-09-05 1999-02-09 Arzneitmittelwerk Dresden G.M.B.H. Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making
DE19532668A1 (de) * 1995-09-05 1997-03-06 Dresden Arzneimittel Neue, antikonvulsiv wirkende 1-Ar(alk)yl-imidazolin-2-one, die in 4-Stellung einen disubstituierten Amin-Rest enthalten, und Verfahren zu deren Herstellung
US5861423A (en) * 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
DE19721580A1 (de) * 1997-05-23 1998-11-26 Dresden Arzneimittel Verwendung von 1-Ar(alk)yl-imidazolin-2-one zur Behandlung von Angst- und Spannungszuständen
WO1999037370A1 (en) 1998-01-22 1999-07-29 Precedence Publishing, Inc. Game using collectibles as playing pieces
GB9821179D0 (en) 1998-09-30 1998-11-25 Merck Sharp & Dohme Therapeutic use
GB9929687D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
GB0122696D0 (en) * 2001-09-20 2001-11-14 Merck Sharp & Dohme Therapeutic agents
US20050070537A1 (en) * 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs

Also Published As

Publication number Publication date
TW200512197A (en) 2005-04-01
ZA200509169B (en) 2006-07-26
AU2004255414A1 (en) 2005-01-20
WO2005004867A2 (en) 2005-01-20
EP1646386A2 (en) 2006-04-19
CN101254189A (zh) 2008-09-03
NZ544251A (en) 2009-12-24
US20080114032A1 (en) 2008-05-15
EP2027856A1 (en) 2009-02-25
US20050032863A1 (en) 2005-02-10
RU2354377C2 (ru) 2009-05-10
CA2531861A1 (en) 2005-01-20
AR045013A1 (es) 2005-10-12
CN1822836A (zh) 2006-08-23
MXPA05013196A (es) 2006-03-09
UA87982C2 (ru) 2009-09-10
KR20060032633A (ko) 2006-04-17
JP2009513539A (ja) 2009-04-02
RU2006104118A (ru) 2006-06-10
NO20060686L (no) 2006-03-14
WO2005004867A3 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
BR0116379A (pt) Antagonistas de receptor y5 de neuropeptìdeo y de uréia de heteroarila
BR0208179A (pt) Composto, composição farmacêutica, métodos para tratar distúrbios associados com o receptor 5-ht6, distúrbios cognitivos, distúrbios da mémoria, psicose, esquizofrenia, e ansiedade, e, uso de um composto
BR0314059A (pt) Compostos heterocìclicos
BR0209558A (pt) Novos compostos de arilsulfonamida para o tratamento de obesidade, diabetes tipo ii e distúrbios do snc
GT200200143A (es) Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales o neuronales
CY1111206T1 (el) Βενζοθειοφαινια υποκατεστημενα με πιπεραζινη για την αγωγη διανοητικων διαταραχων
AR032086A1 (es) Combinaciones de farmacos
ECSP045139A (es) DERIVADOS DE ACETILENO QUE TIENEN ACTIVIDAD ANTAGONISTICA DE MGluR5
CL2007001555A1 (es) Compuestos derivados de 4-amino-pirido[3,2-e]pirazinas; inhibidores de fosfodiesterasa 10 (pde10); procedimeinto de preparacion; composicion framaceutica; combinacion farmaceutica, y sus uso en el tratamiento de trastornos neurologicos y psiquiatricos, tales como esquizofrenia y otros trastornos psicoticos.
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
BR0209812A (pt) Uso de osteopontina para o tratamento e/ou a prevenção de doenças neurológicas
BR0314052A (pt) Imidazolpiridinas e métodos para sua fabricação e uso
TNSN06053A1 (en) 6-substituted anilino purines as rtk inhibitors
BR0314864A (pt) Compostos orgânicos
BR0111892A (pt) Bis-arilsulfonas
BRPI0508084A (pt) método para o tratamento de um distúrbio neurológico, e, uso de meridamicina ou um sal do mesmo
BRPI0411661A (pt) derivados de n-fenil-piperazina e métodos de profilaxia ou tratamento de doenças associadas com o receptor 5ht 2c
CL2003002050A1 (es) Compuestos derivados de 1-piperazin-1,2-dihidroindeno, su composicion farmaceutica y el uso de esta para tratar enfermedades del sistema nervioso central.
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
DE60234118D1 (de) Verbindungen, die für Adenosin A1 und A3 Rezeptoren spezifisch sind, und deren Anwendungen
BRPI0415769A (pt) alcanaminas de diidrobenzofuranila e composições farmacêuticas contendo-as
BR0309486A (pt) Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas
ECSP045156A (es) Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6
BR0113590A (pt) 7-oxo-piridopirimidinas
DE60227576D1 (de) 3,6-DISUBSTITUIERTE AZABICYCLO i3.1.0 -HEXANDERIVATIVE ALS ANTAGONISTEN DES MUSCARINREZEPTORS

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: ELBION GMBH (DE)

Free format text: ALTERADO DE: ELBION AG

B25A Requested transfer of rights approved

Owner name: BOEHRINGER INGELHEIM VETMEDICA GMBH (DE)

Free format text: TRANSFERIDO DE: ELBION GMBH

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.